natgillin/translations-raw huggingface dataset:
Patients exposed to the 10 mg dose seemed to be at increased risk of a CV endpoint in comparison to patients not exposed to the 10 mg dose based on a time model evaluation. 
Na podlagi ocene časovnega modela je videti, da so imeli bolniki, izpostavljeni odmerku 10 mg, povečano tveganje za kardiovaskularni opazovani dogodek v primerjavi z bolniki, ki niso bili izpostavljeni odmerku 10 mg.
There were also no significant differences between the two groups in the incidences of the components of the primary composite endpoint (death from CV causes and nonfatal MI). 
Prav tako ni bilo pomembnih razlik v incidenci komponent primarnega sestavljenega opazovanega dogodka med obema skupinama (smrt zaradi kardiovaskularnih vzrokov in nesmrtni miokardni infarkt).
Although it does not fully explain the findings, a contributor to the increased risk of CV events appears to be the high starting dose and maximum dose used in the SIGNIFY study, exceeding the currently approved maximum dose. 
Videti je, da je bil dejavnik, ki je prispeval k povečanemu tveganju za kardiovaskularne dogodke, velik začetni odmerek in največji odmerek v študiji SIGNIFY, ki je presegel trenutno odobreni največji odmerek, vendar s tem ni mogoče popolnoma razložiti ugotovitev.
Concomitant use of diltiazem/verapamil (which also have an additional heart rate lowering effect) and strong CYP3A4 inhibitors have also shown to increase the incidence of bradycardia events and the risk of MI. Concomitant treatment is currently not recommended but this should be strengthened to a contraindication to minimize the risk of clinically relevant interactions. 
Pokazali so tudi, da sočasna uporaba diltiazema/verapamila (ki ima prav tako dodaten učinek na upočasnitev srčnega utripa) in močnih zaviralcev CYP3A4 poveča incidenco dogodkov bradikardije in tveganje miokardnega infarkta.
MorBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction. 
1 Ocena obolevnosti in umrljivosti za zaviralec If, ivabradin, pri bolnikih s koronarno boleznijo in disfunkcijo levega prekata.
Additional clarifications were also introduced in the DHPC. 
Dodatna pojasnila so vključena tudi v dopis za neposredno komunikacijo z zdravstvenimi delavci.
The SIGNIFY is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, event-driven study which was designed to test the hypothesis that heart rate lowering with ivabradine reduces cardiovascular (CV) event rates in patients with stable coronary artery disease (CAD). 
SIGNIFY je multicentrična, randomizirana, dvojno slepa, s placebom nadzorovana študija z vzporednimi skupinami, ki je temeljila na neželenih dogodkih.
Although not reaching statistical significance, similar trends were observed for the individual components of CV death and non-fatal myocardial infarction (MI). 
Podobno gibanje so opazili pri posameznih komponentah kardiovaskularne smrti in nesmrtnega miokardnega infarkta (MI), vendar niso dosegli statistične pomembnosti.
Study assessInG the morbi-mortality beNefits of the If inhibitor ivabradine in patients with coronary arterY disease. 
3 Študija za ocenjevanje koristi zaviralca If, ivabradina, za obolevnost in umrljivost pri bolnikih s koronarno arterijsko boleznijo.
Scientific conclusions 1 - PRAC recommendation 
- Priporočilo odbora PRAC
Systolic Heart failure treatment with the If inhibitor ivabradine Trial. 
2 Preskušanje zdravljenja sistoličnega srčnega popuščanja z zaviralcem If, invabradinom.
Ivabradine, a specific heart rate lowering agent, has demonstrated symptomatic improvement of angina symptoms in patients with stable CAD. A large study in patients with CAD and left ventricular dysfunction (BEAUTIFUL study) could not demonstrate a benefit in terms of CV outcome. 
Pri ivabradinu, posebni učinkovini za upočasnitev srčnega utripa, so dokazali simptomatsko izboljšanje simptomov angine pektoris pri bolnikih s stabilno koronarno arterijsko boleznijo.
dose in the SIGNIFY study (higher than the current approved 7.5 mg b.i.d. 
Pri bolnikih v študiji SIGNIFY, pri katerih so odmerek povečali na največ 10 mg dvakrat na dan (več kot trenutno odobreni odmerek 7,5 mg dvakrat na dan), se je večina opazovanih dogodkov pojavila, ko so bolniki jemali največji odmerek.
BACKGROUND INFORMATION 
OSNOVNE INFORMACIJE
A Decision was issued by the European Commission on 4 July 2006. 
Odločbo je Evropska Komisija izdala dne 4. julija 2006.
The referral procedure started on 19 September 2005. 
Postopek se je začel dne 19. septembra 2005.
The divergences identified at the start of the referral were resolved. 
Razlike, ugotovljene na začetku napotitvenega postopka, so bile odpravljene.
• Travelling to any country that requires an International Certificate of Vaccination for entry (which may or may not depend on the previous itinerary). 
• ki potujejo v katerokoli državo, ki za vstop zahteva Mednarodno potrdilo o cepljenju (kar je lahko odvisno ali neodvisno od predhodnega potovalnega načrta)
• Travelling to, passing through or living in an endemic area. 
• ki potujejo, se prehodno zadržujejo ali živijo na endemičnem področju,
Active immunisation against yellow fever in persons from 9 months of age: 
aktivna imunizacija proti rumeni mrzlici pri osebah, starih več kot 9 mesecev:
• Handling potentially infectious materials (e.g. laboratory personnel). 
• ki rokujejo s potencialno kužnimi snovmi (npr. laboratorijsko osebje).
The CHMP gave a positive opinion on 27 April 2006 recommending the harmonisation of the SPC for STAMARIL and associated names. 
CHMP je 27. aprila 2004 izdal pozitivno mnenje, s katerim priporoča uskladitev SPC za STAMARIL in z njim povezana imena.
STAMARIL is a viral vaccine and the antigen of the vaccine act prophylactic by stimulating an immune response against the above-yellow fever. 
STAMARIL je virusno cepivo in antigen cepiva deluje profilaktično tako, da stimulira imunski odgovor proti zgoraj omenjeni rumeni mrzlici.
The CHMP having considered the Rapporteur and the Co-Rapporteur assessment reports, the scientific discussion within the Committee and the comments from the Marketing Authorisation Holders (MAH), was of the opinion that the benefit/risk ratio of STAMARIL and associated names is considered to be positive in the following indications: 
Ob upoštevanju poročil o oceni zdravila poročevalca in so-poročevalca, znanstvenih razprav znotraj odbora in pripomb imetnikov dovoljenj za promet z zdravilom (MAH) je CHMP menil, da je razmerje med koristmi in tveganji zdravila STAMARIL in z njim povezanih imen pozitivno v naslednjih indikacijah:
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC in Annex III. 
Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II skupaj z dopolnjenim Povzetkom glavnih značilnosti zdravila (SPC) v Dodatku III.
The active substance of STAMARIL is a live attenuated yellow fever virus. 
Zdravilna učinkovina v zdravilu STAMARIL je živ, oslabljen virus rumene mrzlice.
On 11 August 2005, Sanofi Pasteur MSD on behalf of all the Marketing Authorisation Holders (see Annex I) presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the national SPCs of the medicinal product STAMARIL and associated names. 
Dne 11. avgusta 2005 je Sanofi Pasteur MSD v imenu vseh imetnikov dovoljenj za promet (glej Dodatek I) na EMEA predložil predlog za postopek v skladu s členom 30 Direktive 2001/83/ES, kot je bila spremenjena, za uskladitev nacionalnih Povzetkov glavnih značilnosti (SPC) zdravila STAMARIL in z njim povezanih imen.
London, 4 July 2006 EMEA/169383/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) SUMMARY INFORMATION ON REFERRAL OPINION PURSUANT TO ARTICLE 30 OF COUNCIL DIRECTIVE 2001/83/EC FOR STAMARIL and associated names (See Annex I) International Non-Proprietary Name (INN): Live attenuated yellow fever virus 
London, 4.7. 2006 EMEA/169383/2006 ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) POVZETEK MNENJA PO POSTOPKU, IZVEDENEM V SKLADU S ČLENOM 30 DIREKTIVE SVETA 2001/83/ES ZA STAMARIL in z njim povezana imena (Glej Dodatek I) Mednarodno nelastniško ime (INN): Živ, oslabljen virus rumene mrzlice
Different Summaries of Product Characteristics (SPC) had been authorised, based on national, divergent decisions from the authorisations in the EU Member States. 
Na podlagi nacionalnih, različnih odločitev pristojnih organov v državah članicah EU so bili odobreni različni Povzetki glavnih značilnosti zdravila (SPC).
London, 20 November 2008 Doc. 
London, 20. novembra 2008 Sklic dok.
In both cases, all medicines were to be started at the same time. 
V obeh primerih bi se vsa zdravila uvedla sočasno.
In both groups, trastuzumab treatment was continued for a year. 
V obeh skupinah je zdravljenje s trastuzumabom trajalo eno leto.
The main measure of effectiveness was how long the patients survived until their cancer came back. 
Glavno merilo učinkovitosti je bil čas preživetja bolnikov do ponovitve raka.
The evaluation had finished and the CHMP had given a negative opinion. 
Postopek ocenjevanja je bil zaključen in CHMP je izrazil negativno mnenje.
The company had initiated an appeal process, but this had not yet finished when the company withdrew. 
Družba je sprožila pritožbeni postopek, vendar se ta še ni zaključil, ko je družba podala zahtevek za umik.
International non-proprietary name (INN): docetaxel 
Mednarodno nelastniško ime (INN): docetaksel
If you are in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you. 
Če ste vključeni v klinično preskušanje ter potrebujete več informacij o zdravljenju, se obrnite na zdravnika, ki vam je predpisal zdravljenje.
The letters from the company notifying the EMEA of the withdrawal of the application are available here and here. 
Dopisa, s katerima družba agencijo EMEA obvešča o umiku vloge, sta na voljo tukaj in tukaj.
Docetaxel blocks the ability of cells to destroy the internal ‘skeleton' that allows them to divide and multiply. 
Docetaksel blokira sposobnost celic za uničevanje notranjega „skeleta“, ki jim omogoča deljenje in razmnoževanje.
What were the main concerns of the CHMP? 
Kateri so bili glavni zadržki CHMP?
With the skeleton still in place, the cells cannot divide and they eventually die. 
Ker skelet ostane nespremenjen, se celice ne morejo deliti in sčasoma odmrejo.
The study compared the effectiveness of the following treatment combinations, which were used in addition to surgery: 
V študiji so primerjali uèinkovitost naslednjih kombinacij zdravil, ki so se uporabila poleg operativnega posega:
Docetaxel affects not only cancer cells, but also non-cancer cells such as blood cells, which can cause side effects. 
Docetaksel ne vpliva le na rakave celice, ampak tudi na nerakave celice, kot so krvne celice, kar lahko povzroči neželene učinke.
There are no consequences on the use of Taxotere/Docetaxel Winthrop in its authorised indications, for which the balance of benefits and risks remains unchanged. 
Umik nima nobenih posledic za uporabo zdravila Taxotere/Docetaxel Winthrop za odobrene indikacije, pri katerih ostaja razmerje med koristmi in tveganji nespremenjeno.
It is used in breast cancer that is advanced or ‘metastatic' (has spread to other parts of the body), and in breast cancer that can be treated with surgery. 
Uporablja se pri raku dojke, ki je napredoval ali ima zasevke (se je razširil na druge dele telesa), ter pri raku dojke, ki ga je možno zdraviti z operativnim posegom.
• together with trastuzumab (another anticancer medicine), following treatment with doxorubicin and cyclophosphamide; 
• skupaj s trastuzumabom (drugim zdravilom proti raku) po zdravljenju z doksorubicinom in ciklofosfamidom;
• together with trastuzumab and carboplatin (another anticancer medicine). 
• skupaj s trastuzumabom in karboplatinom (drugim zdravilom proti raku).
The CHMP was also concerned that the company did not provide sufficient clinical evidence to justify the use of the combination of Taxotere/Docetaxel Winthrop, carboplatin and trastuzumab. 
Odbor je menil tudi, da družba ni predložila zadostnih kliniènih dokazov za utemeljitev uporabe kombinacije zdravila Taxotere/Docetaxel Winthrop, karboplatina in trastuzumaba.
On 14 November 2008, Sanofi-Aventis Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Taxotere/Docetaxel Winthrop, to add the treatment of patients with operable breast cancer whose tumours overexpress HER2 in combination with trastuzumab, with or without carboplatin. 
Družba Sanofi-Aventis Pharma S.A. je dne 14. novembra 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za novo indikacijo za zdravilo Taxotere/Docetaxel Winthrop, tj. za dodatek zdravljenja bolnic z operabilnim rakom dojke, katerega tumorji imajo čezmerno izražajo HER2, v kombinaciji s trastuzumabom in karboplatinom ali brez njega.
The CHMP was concerned that it was not possible to establish the benefits of the treatment combinations including Taxotere/Docetaxel Winthrop when used in addition to surgery, because of the way the single main study was designed. 
CHMP je menil, da ni bilo mogoèe ugotoviti koristi kombinacij zdravljenja, vkljuèno z zdravilom Taxotere/Docetaxel Winthrop, kot dodatkov po operativnem posegu zaradi naèina zasnove edine glavne študije.
Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Taxotere/Docetaxel Winthrop 
Vprašanja in odgovori v zvezi z umikom vloge za spremembo dovoljenja za promet z zdravilom Taxotere/Docetaxel Winthrop
Taxotere/Docetaxel Winthrop was also expected to be used to treat breast cancer that can be treated with surgery when the cancer has been shown to be ‘expressing' large amounts of HER2: this is a type of cancer that produces (expresses) a specific protein called HER2 in large quantities on the surface of the tumour cells. 
Zdravilo Taxotere/Docetaxel Winthrop naj bi se uporabljalo za zdravljenje raka dojke, ki ga je mogoèe zdraviti z operativnim posegom, èe se ugotovi, da rak „izraža“ velike kolièine HER2: to je vrsta raka, ki na površini rakavih celic v velikih kolièinah tvori (izraža) doloèeno beljakovino, imenovano HER2.
It contains the active substance docetaxel. 
Vsebuje zdravilno uèinkovino docetaksel.
Taxotere/Docetaxel Winthrop is an anticancer medicine. 
Taxotere/Docetaxel Winthrop je zdravilo proti raku.
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had given a negative opinion and did not recommend a marketing authorisation for Taxotere/Docetaxel Winthrop in the treatment of patients with operable breast cancer whose tumours overexpress HER2 in combination with trastuzumab, with or without carboplatin. 
Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je do umika vloge zastavil CHMP, je Odbor izrazil negativno mnenje in ni priporočil odobritve dovoljenja za promet z zdravilom Taxotere/Docetaxel Winthrop, namenjenim zdravljenju bolnikov z rakom dojke, ki ga je možno zdraviti z operativnim posegom in katerega tumorji čezmerno izražajo HER2, v kombinaciji s trastuzumabom in s karboplatinom ali brez njega.
Taxotere/Docetaxel Winthrop has been studied in one main study involving over 3,000 women with HER2-expressing breast cancer that could be treated with surgery. 
Zdravilo Taxotere/Docetaxel Winthrop je bilo prouèeno v eni glavni študiji, v katero je bilo vkljuèenih veè kot 3 000 žensk z rakom dojke, ki je izražal HER2 in ga je bilo možno zdraviti z operativnim posegom.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Taxotere/Docetaxel Winthrop. 
Družba je obvestila CHMP, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih zdravila Taxotere/Docetaxel Winthrop.
What are the consequences of the withdrawal for patients undergoing clinical trials with Taxotere/Docetaxel Winthrop? 
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preskušanjih zdravila Taxotere/Docetaxel Winthrop?
What is happening for Taxotere/Docetaxel Winthrop for the treatment of other types of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer? 
Kakšne so posledice za zdravilo Taxotere/Docetaxel Winthrop, indicirano za zdravljenje drugih vrst raka dojke, nedrobnoceličnega pljučnega raka, raka prostate, adenokarcinoma želodca ter raka glave in vratu.
In these patients, Taxotere/Docetaxel Winthrop is used in addition to surgery to remove the tumour, together with doxorubicin and cyclophosphamide (other anticancer medicines). 
Pri teh bolnicah se zdravilo Taxotere/Docetaxel Winthrop uporablja kot dodatek operativnemu posegu za odstranitev tumorja skupaj z doksorubicinom in ciklofosfamidom (drugi dve zdravili proti raku).
Taxotere/Docetaxel Winthrop was expected to be used in addition to surgery to remove the tumour in the following treatment combinations: 
Zdravilo Taxotere/Docetaxel Winthrop naj bi se uporabljalo kot dodatek operativnemu posegu za odstranitev tumorja v naslednjih kombinacijah zdravljenja:
Taxotere/Docetaxel Winthrop is also used in advanced or metastatic non-small cell lung cancer, in prostate cancer, in metastatic gastric adenocarcinoma (a type of stomach cancer) and in advanced head and neck cancer. 
Zdravilo Taxotere/Docetaxel Winthrop se uporablja tudi pri napredovalem ali metastatskem nedrobnoceličnem pljučnem raku , raku prostate, metastatskem adenokarcinomu želodca (vrsta želodčnega raka) in pri napredovalem raku glave in vratu.
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Taxotere/Docetaxel Winthrop had not been sufficiently demonstrated and any benefits did not outweigh the identified risks. 
CHMP je v času umika menil, da koristi zdravila Taxotere/Docetaxel Winthrop niso bile zadostno dokazane in da ne odtehtajo znanih tveganj.
Taxotere/Docetaxel Winthrop is a concentrate and solvent, which are made up into a solution for infusion (drip into a vein). 
Zdravilo Taxotere/Docetaxel Winthrop je koncentrat in vehikel, ki se uporabljata za pripravo raztopine za infundiranje (vnašanje po kapljicah v veno).
The active substance in Taxotere/Docetaxel Winthrop, docetaxel, belongs to the group of anticancer medicines known as the ‘taxanes'. 
Zdravilna učinkovina zdravila Taxotere/Docetaxel Winthrop, docetaksel, spada v skupino zdravil proti raku, ki jim pravimo „taksani“.
What is Taxotere/Docetaxel Winthrop? 
Kaj je zdravilo Taxotere/Docetaxel Winthrop?
• the combination of Taxotere/Docetaxel Winthrop, trastuzumab and carboplatin for 18 weeks. 
• 18-tedenska kombinacija zdravila Taxotere/Docetaxel Winthrop s trastuzumabom in karboplatinom.
How is Taxotere/Docetaxel Winthrop expected to work? 
Kako naj bi zdravilo Taxotere/Docetaxel Winthrop delovalo?
• the combination of doxorubicin and cyclophosphamide for 12 weeks, followed by 
• 12-tedenska kombinacija doksorubicina in ciklofosfamida, čemur je sledila 12-tedenska uporaba zdravila Taxotere/Docetaxel Winthrop s trastuzumabom ali brez njega;
What was Taxotere/Docetaxel Winthrop expected to be used for? 
Za kaj naj bi se zdravilo Taxotere/Docetaxel Winthrop uporabljalo?
Slovak Republic ratiopharm International GmbH 
Slovaška ratiopharm International GmbH
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states 
Dodatek I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
Germany mibe GmbH Arzneimittel Münchener Str. 15 
Nemčija mibe GmbH Arzneimittel Münchener Str. 15
Germany ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm Germany 
Nemčija ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm Germany
Miacalcic 200 i.e./odmerek pršilo za nos, raztopina 
Miacalcic 200 i.e./odmerek pršilo za nos, raztopina pršilo za nos, raztopina nazalna uporaba
Miacalcic Nasal 100 100 IU 
Miacalcic Nasal 100 100 i.e.
200 IU/dose, 2000 IU/ML 
200 i.e./odmerek, 2000 i.e./ML
400 IU 
400 i.e.
Miacalcic Nasal 200 200 IU 
Miacalcic Nasal 200 200 i.e.
Calcitonina Wander 200 200 IU/dose nebuliser solution nasal use 
Calcitonina Wander 200 200 i.e./odmerek inhalacijska raztopina za nebulator nazalna uporaba
2200 i.e./ml 
200 i.e. i.m.
TONOCALCIN 200 IU nosová aerodisperzia 200 IU/0,1 ml 
TONOCALCIN 200 IU nosová aerodisperzia 200 i.e./0,1 ml pršilo za nos, raztopina nazalna uporaba
Calcitonin 'Novartis' 50 I.E./ml - Lösung zur Injektion und Infusion solution for injection/infusion subcutaneous use, intramuscular use, intravenous use 
Calcitonin 'Novartis' 50 I.E./ml - Lösung zur Injektion und Infusion raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
Miacalcic Solution for Injection 100IU/ml solution for injection subcutaneous, intramuscular and intravenous use 
Miacalcic Solution for Injection 100IU/ml raztopina za injiciranje subkutana, intramuskularna in intravenska uporaba
Calcitonine-Sandoz 100 IE/ml, oplossing voor injectie en infusie solution for injection/infusion subcutaneous use, intramuscular use, intravenous use 
Calcitonine-Sandoz 100 IE/ml, oplossing voor injectie en infusie raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
Calcitonin 'Novartis' 100 I.E./ml - Lösung zur Injektion und Infusion solution for injection/infusion subcutaneous use, intramuscular use, intravenous use 
Calcitonin 'Novartis' 100 I.E./ml - Lösung zur Injektion und Infusion raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
0,25 mg powder and solvent for solution for injection intramuscular use, intravenous use, subcutaneous use 
0,25 mg prašek in vehikel za raztopino za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Karil 100 I.E. Injektionslösung solution for injection intravenous use, intramuscular use, subcutaneous use 
Karil 100 I.E. Injektionslösung raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
TONOCALCIN 100 IU nosová aerodisperzia 100 IU/0,1 ml 
TONOCALCIN 100 IU nosová aerodisperzia 100 i.e./0,1 ml pršilo za nos, raztopina nazalna uporaba
0,50 mg powder and solvent for solution for injection intramuscular use, intravenous use, subcutaneous use 
0,50 mg prašek in vehikel za raztopino za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Calcitonin 100 I.E.Rotexmedica solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin 100 I.E.Rotexmedica raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
100 IU/1ML AMP solution for injection intramuscular use 
100 i.e./1 ml amp raztopina za injiciranje intramuskularna uporaba
Calcitonine Sandoz solution for injection intramuscular use, intravenous use, subcutaneous use 
Calcitonine Sandoz raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
Calcitonin-CT 100 I.E./0,1ml Nasenspray 100 IU / dose 
Calcitonin-CT 100 I.E./0,1 ML Nasenspray 100 i.e./odmerek pršilo za nos, raztopina nazalna uporaba
Calcitonin 50 I.E.Rotexmedica solution for injection intravenous use, intramuscular use, subcutaneous use 
Calcitonin 50 I.E.Rotexmedica raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
CALCO 100 NE/ml injekció solution for injection subcutaneous use, intramuscular use, intravenous use 
CALCO 100 NE/ml injekció raztopina za injiciranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
200 IU/dose nasal spray, liquid nasal use 
200 i.e./odmerek pršilo za nos, tekočina nazalna uporaba
powder and solvent for solution for injection intramuscular use, subcutaneous use 
prašek in vehikel za raztopino za injiciranje intramuskularna uporaba, subkutana uporaba